Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) is a global healthcare solutions provider focused on medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. This news page aggregates company announcements, press releases, and other updates related to GE HealthCare’s business activities and capital markets disclosures.
Visitors can find news about GE HealthCare’s collaborations with health systems, governments, and academic institutions, such as agreements to supply advanced CT scanners under national programs, multi-year care alliances with medical centers, and research initiatives in radiation therapy and oncology. The company also issues news on product and technology developments, including imaging systems, AI-powered reconstruction tools, radiology workflow software, and other innovations that it associates with advancing precision care.
GE HealthCare’s news flow includes corporate and investor-focused items as well. Examples include announcements of upcoming earnings releases, participation in healthcare and investor conferences, and responses to shareholder-related matters such as unsolicited mini-tender offers. These communications provide context on how the company presents its strategy, financing activities, and interactions with the capital markets.
Because GE HealthCare emphasizes integrated solutions across Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, many news items highlight how these businesses work together in specific projects or collaborations. Readers can expect coverage of topics such as AI-enabled imaging, diagnostic access initiatives, training and innovation hubs, and alliances aimed at supporting more efficient and precise care. Investors and observers who follow GEHC news can use this page as a centralized view of the company’s publicly released information and developments over time.
GE HealthCare announced results from the COSMOS pilot study evaluating their Portrait Mobile monitoring solution in post-surgical settings. The two-phase, 250-patient study showed that 82% of alarms were considered informative or useful by clinicians, with an average of less than three alarms per patient per day. The system demonstrated effectiveness in encouraging clinical intervention while reducing alarm fatigue. Notable outcomes include approximately 25% reduction in vital sign abnormalities and 60% more oxygen therapy interventions in monitored patients compared to those with standard intermittent monitoring. The study highlights Portrait Mobile's potential to enable early detection of patient deterioration and timely clinical intervention in medical-surgical units.
GE HealthCare has received FDA 510(k) clearance for its SIGNA™ MAGNUS, a 3.0T head-only MRI scanner designed for advanced neuroimaging. The system features an innovative asymmetrical head-only gradient coil design that achieves higher gradient performance with reduced inner diameter. The technology delivers gradient amplitude and slew rate superior to conventional whole-body MRI systems, with performance levels of 300 mT/m and 750 T/m/s. The system enables shorter scan times and enhanced spatial resolution while maintaining the same power requirements as the SIGNA Premier 3.0T system. Four investigational MAGNUS systems have already been installed at major medical centers.
GE HealthCare (Nasdaq: GEHC) has announced a new initiative with AMN Healthcare to address the critical shortage of radiologic technologists in healthcare. The shortage is attributed to clinician burnout, COVID-19 impacts, and demand outpacing the number of trained professionals, with 42% of clinicians considering leaving healthcare. The collaboration combines GE HealthCare's technology training expertise across multiple imaging modalities with AMN Healthcare's workforce solutions to help healthcare providers meet staffing needs. The initiative aims to develop capacity and train the next generation of rad techs across both hospital and outpatient settings.
GE HealthCare (GEHC) and RadNet's DeepHealth announced a strategic collaboration to advance AI in medical imaging. The partnership will combine GE HealthCare's imaging expertise with RadNet's DeepHealth AI solutions to create SmartTechnology™ solutions. Their first initiative integrates DeepHealth's AI-powered SmartMammo™ with GE's Senographe Pristina™ mammography system to enhance breast cancer screening. The collaboration includes Smart Alerts, aimed at enabling rapid AI processing for potentially suspicious lesions. GE HealthCare will distribute SmartMammo and other DeepHealth solutions in the United States as part of their imaging technologies portfolio.
GE HealthCare Technologies (Nasdaq: GEHC) has announced the pricing of a secondary public offering of 13,281,302 shares of its common stock. The company will not receive any proceeds from the sale, as GE Aerospace plans to exchange these shares for debt held by Morgan Stanley Bank. Following this debt-for-equity exchange, Morgan Stanley & Co. will sell the shares to underwriters. J.P. Morgan, Citigroup, and Morgan Stanley are serving as lead joint book-running managers. The offering is expected to close on November 12, 2024, subject to customary conditions.
GE HealthCare Technologies (Nasdaq: GEHC) announced a secondary public offering of 13,281,302 shares of common stock. The company will not sell any shares or receive proceeds from the offering. GE Aerospace plans to exchange these shares for debt held by Morgan Stanley Bank before the offering closes. Morgan Stanley & Co. will then sell the shares to underwriters. J.P. Morgan, Citigroup, and Morgan Stanley are serving as lead joint book-running managers for the offering.
GE HealthCare (Nasdaq: GEHC) announced it will host its 2024 Investor Day on Thursday, November 21, 2024, at Nasdaq MarketSite in New York, NY. The event will feature presentations from the management team covering growth strategies, technology portfolio, and business vision. A technology showcase will be available for in-person attendees following the presentations. Registration is required for attendance. Investors can access the live webcast through the company's investor relations website, where related materials and replay will also be available.
GE HealthCare (GEHC) reported Q3 2024 financial results with revenues of $4.9 billion, up 1% year-over-year. Net income margin improved to 9.7% from 7.8%, while Adjusted EBIT margin increased to 16.3% from 15.4%. Diluted EPS rose to $1.02 from $0.83, and Free cash flow reached $651 million, up from $570 million. The company saw growth in U.S. markets and Pharmaceutical Diagnostics, offset by softness in China. The company raised the low end of its full-year 2024 Adjusted EBIT margin and Adjusted EPS guidance, while noting organic revenue growth is trending toward the lower end of the 1-2% range.
GE HealthCare has announced CareIntellect for Oncology, a new cloud-first application that uses generative AI to consolidate multi-modal patient data into a single view. This application aims to help clinicians quickly understand disease progression and inform proactive interventions. Key features include:
- Summarizing clinical notes and reports
- Organizing structured and unstructured data
- Supporting treatment response assessments
- Helping assess clinical trial eligibility
- Tracking adherence to treatment protocols
Initially focusing on prostate and breast cancer, CareIntellect for Oncology is designed to reduce the time clinicians spend reviewing patient histories from hours to minutes. Tampa General Hospital and UT Southwestern Medical Center will be early evaluators, with wider U.S. availability planned for 2025.
GE HealthCare (Nasdaq: GEHC) has unveiled its new AI Innovation Lab, showcasing five early-concept AI projects aimed at revolutionizing healthcare. These innovations include:
1. Health Companion: An agentic AI project to provide multi-disciplinary medical team insights.
2. Triple negative breast cancer recurrence prediction research with Emory University.
3. Care companion initiative for enhancing maternal and infant care.
4. Multi-modal X-ray foundation model for full-body imaging analysis.
5. AI-powered mammography screening efficiency tool.
Additionally, GE HealthCare has submitted a 510(k) to the FDA for an AI-powered fetal heart rate interpretation feature. These projects are part of GE HealthCare's broader AI and digital strategy, leveraging cloud technology to drive AI development at scale.